Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-01-28

Clinical Trial Update: Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid. [Phase 2]

View source ↗

Summary

Phase II trial evaluating Florbetaben PET imaging (BAY94-9172) for detection/exclusion of cerebral beta-amyloid; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • florbetaben (florbetaben)

Snippet

Sponsor: Life Molecular Imaging SA | Conditions: Down Syndrome, Amyloid Beta-protein | Phase 2 | Status: COMPLETED | Results posted: 2014-01-28